Jane Street’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-52,920
Closed -$12.2K – 11040
2024
Q4
$12.2K Buy
+52,920
New +$63.5K ﹤0.01% 9165
2024
Q3
– Sell
-39,181
Closed -$202K – 10611
2024
Q2
$202K Sell
39,181
-133,336
-77% -$701K ﹤0.01% 8371
2024
Q1
$923K Buy
172,517
+151,382
+716% +$1.05M ﹤0.01% 5566
2023
Q4
$165K Buy
+21,135
New +$72.4K ﹤0.01% 8343
2023
Q1
– Sell
-16,319
Closed -$58.6K – 10122
2022
Q4
$58.6K Buy
+16,319
New +$70.8K ﹤0.01% 8310
2022
Q3
– Sell
-1,709
Closed -$16K – 10653
2022
Q2
$16K Buy
1,709
+329
+24% +$3.08K ﹤0.01% 9223
2022
Q1
$16K Sell
1,380
-1,280
-48% -$22.9K ﹤0.01% 10000
2021
Q4
$87K Sell
2,660
-5,201
-66% -$211K ﹤0.01% 9313
2021
Q3
$352K Buy
7,861
+2,557
+48% +$125K ﹤0.01% 7883
2021
Q2
$289K Buy
5,304
+1,524
+40% +$90.2K ﹤0.01% 8209
2021
Q1
$283K Sell
3,780
-1,723
-31% -$179K ﹤0.01% 7785
2020
Q4
$597K Buy
+5,503
New +$502K ﹤0.01% 5469

Other funds holding SYRS

Jane Street's SYRS Position: Q1 2025 in Review

Jane Street sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 52,920 shares — an estimated $12.2K sold.

Jane Street first reported a position in SYRS in Q4 2020 and held it in 12 quarters. The position peaked at $923K in Q1 2024. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • Jane Street reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Jane Street sold 52,920 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $12.2K.
  • Jane Street first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 12 quarters.
  • Jane Street's Syros Pharmaceuticals, Inc. Common Stock position peaked at $923K in Q1 2024.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on Jane Street's 13F filing for Q1 2025, filed 14 May 2025.